Home World News Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with... World News Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC By Ogkologos - May 7, 2026 296 0 Facebook Twitter Google+ Pinterest WhatsApp Updated efficacy and safety results from the TRUST-I study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer May 10, 2018 Bowel Cancer Data Reinforce Need to Reduce Unnecessary Antibiotic Use [ESMO... July 2, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Belantamab Mafodotin July 29, 2020 11 Children Orphaned and Unable to Pay for Funeral After Their... April 25, 2019 Load more HOT NEWS New Measures to Avoid Handling Errors with Leuprorelin Depot Medicines Announcing ‘Cancer Revolution’ – a world-first exhibition to engage people with... EMA Recommends Refusal of the Marketing Authorisation for Tagraxofusp “White Bagging” Harmful to Patients, Requires Them to Use Insurance-Approved Formulary...
